Amendments to the Claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-31 (Cancelled)

32. (Currently Amended) A compound of Formula I:



Formula I

wherein:

n is 0, 1, or 2;

R_1 is OH, C_1 to C_{12} alkoxy, C_1 to C_{12} substituted alkoxy, aryloxy, O-glucosyl or imino;

R_2 is OH, C_1 to C_{12} alkoxy, C_1 to C_{12} substituted alkoxy, O-glucosyl, oxo, alkyl or imino;

R_3, R_4, R_5, R_6, R_7, A, B, C, D and E are each independently H, halogen selected from the group consisting of bromo, iodo, fluoro and chloro, OH, C_1 to C_{12} alkoxy, C_1 to C substituted alkoxy, aryloxy, O-glucosyl, C_1 to C_{12} alkyl or C_1 to C_{12} substituted alkyl; provided that at least one of R_6 and R_7 is selected from the group consisting of bromo, iodo, fluoro and chloro;

wherein R_1 and R_2, or R_1 and R_4 may form together a lactone which is optionally substituted;

wherein the bonds between C_3:C_7, C_4:C_5, and C_9:C_{10} may independently be double bonds or single bonds;

~~provided that at least one of R_3, R_4, R_5, R_6, R_7, A, B, C, D and E is a halogen; and provided that, if A is the only halogen in the compound, that A is not fluoro;~~

or a derivative of said formula, wherein the derivative has at least one of the following: a lower acyl side chain at C_3 (free acid or ester or conjugate), a keto or hydroxy (free hydroxy or ester) moiety at the C_6 carbon, or an n-pentenyl or n-pentyl side chain at C_7;

including salts, hydrates, solvates, polymorphs, optical isomers, enantiomers, diastereomers, and mixtures thereof.

33. (Previously Presented) The compound of claim 32, wherein the bond between C_9 and C_{10} is a single bond.

34. (Previously Presented) The compound of claim 32, wherein R_2 is oxo.

35. (Cancelled)

36. (Currently Amended) The compound of claim 32, wherein <u>each of</u> A, B, R_6 and R_7 [[are]] <u>is</u> selected from bromo, iodo, fluoro and chloro.

37. (Previously Presented) The compound of claim 32, wherein R_1 is alkoxy.

38. (Previously Presented) The compound of claim 32, wherein R_3, R_4 and R_5 are each H.

39. (Previously Presented) The compound of claim 32, wherein C, D and E are each H.

40. (Previously Presented) The compound of claim 32, wherein: n is 0; the bonds between C_3:C_7, C_4:C_5, and C_9:C_{10} are single bonds; R_1 is methoxy; R_2 is oxo; R_3, R_4, R_5, A, B, C, D and E are each H; and R_6 and R_7 are each bromo.

41. (Previously Presented) The compound of claim 32, wherein: n is 0; the bonds between C_3:C_7, C_4:C_5, and C_9:C_{10} are single bonds; R_1 is methoxy; R_2 is O bound through a double bond to the carbon in position 6 thereby forming a carbonyl group; R_3, R_4, R_5, C, D and E are each H; and A, B, R_6 and R_7 are each bromo.

42. (Previously Presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier, and as an active ingredient a compound of claim 32.

43. (Previously Presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier, and as an active ingredient a compound of claim 40.

44. (Previously Presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier, and as an active ingredient a compound of claim 41.

45. (Previously Presented) A method for reduction of the growth of cancer cells, comprising exposing the cancer cells to a therapeutically effective amount of a compound of claim 32.

46. (Currently Amended) The method of claim 45 wherein the cancer is ~~selected from the group consisting of:~~ a mammalian cancer ~~and human cancer~~.

Claims 47-50 (Cancelled)

51. (Previously Presented) A method for the treatment of cancer comprising administering to the subject in need thereof a pharmaceutical composition containing as an active ingredient a therapeutically effective amount of the compound according to claim 32.

52. (Previously Presented) A method for the treatment of cancer comprising administering to the subject in need thereof a pharmaceutical composition containing as an active ingredient a therapeutically effective amount of the compound according to claim 40.

53. (Currently Amended) The method according to claim 51, wherein the cancer is selected from the group consisting of carcinoma, sarcoma, adenoma, hepatocellular carcinoma, hepatoblastoma, rhabdomyosarcoma, esophageal carcinoma, thyroid carcinoma, ganglioblastoma, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphagiosarcoma, synovioama, Ewing's tumor, leimyosarcoma, rhabdotheliosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, renal cell carcinoma, hematoma, bile duct carcinoma, melanoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell and non-small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocyoma, medulloblastoma, craniopharyngioma, ependynoma, pinealoma, retinoblastoma, rectal carcinoma, cancer of the thyroid, head and neck cancer, brain cancer, ~~cancer of the peripheral nervous system, cancer of the central nervous system,~~ neuroblastoma, cancer of the endometrium, lymphoproliferative diseases, hematopoietic malignancies including all types of leukemia and

lymphoma including: acute myelogenous leukemia, acute myelocytic leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, mast cell leukemia, multiple myeloma, myeloid lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, as well as metastasis of all the above.

Claim 54 (Cancelled)

55. (Previously Presented) The method of claim 51, wherein the cancer is selected from the group consisting of prostate cancer, breast cancer, skin cancer, colon cancer, lung cancer, pancreatic cancer, lymphoma, leukemia, head and neck cancer, kidney cancer, ovarian cancer, bone cancer, liver cancer, melanoma and thyroid cancer.

56. (New) The compound of claim 32, wherein R_6 and R_7 are each F.

57. (New) The compound of claim 32, wherein R_6 and R_7 are each I.

58. (New) The compound of claim 32, wherein R_6 and R_7 are each Cl.

59. (New) The compound of claim 32, wherein R_6 and R_7 are each Br.

60. (New) The compound of claim 32, wherein one of R_6 and R_7 is Br and the other is OH.

61. (New) The compound of claim 32, wherein one of R_6 and R_7 is I and the other is OCH_3.

62. (New) A method for the treatment of cancer comprising administering to the subject in need thereof a pharmaceutical composition containing as an active ingredient a therapeutically effective amount of the compound of Formula I:



Formula I

wherein:

n is 0, 1, or 2;

R_1 is OH, C_1 to C_{12} alkoxy, C_1 to C_{12} substituted alkoxy, aryloxy, O-glucosyl or imino;

R_2 is OH, C_1 to C_{12} alkoxy, C_1 to C_{12} substituted alkoxy, O-glucosyl, oxo, alkyl or imino;

R_3, R_4, R_5, R_6, R_7, A, B, C, D and E are each independently H, halogen, OH, C to C alkoxy, C to C substituted alkoxy, aryloxy, O-glucosyl, C_1 to C_{12} alkyl or C_1 to C_{12} substituted alkyl;

wherein R_1 and R_2, or R_1 and R_4 may form together a lactone which is optionally substituted;

wherein the bonds between C_3:C_7, C_4:C_5, and C_9:C_{10} may independently be double bonds or single bonds;

provided that at least one of R_3, R_4, R_5, R_6, R_7, A, B, C, D or E is a halogen; and provided that, if A is the only halogen in the compound, that A is not fluoro;

or a derivative of said formula, wherein the derivative has at least one of the following: a lower acyl side chain at C_3 (free acid or ester or conjugate), a keto or hydroxy (free hydroxy or ester) moiety at the C_6 carbon, or an n-pentenyl or n-pentyl side chain at C_7;

including salts, hydrates, solvates, polymorphs, optical isomers, enantiomers, diastereomers, and mixtures thereof.

63. (New) The method of claim 62, wherein the cancer is selected from the group consisting of carcinoma, sarcoma, adenoma, hepatocellular carcinoma, hepatoblastoma, rhabdomyosarcoma, esophageal carcinoma, thyroid carcinoma, ganglioblastoma, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphagiosarcoma, synovioama, Ewing's tumor, leimyosarcoma, rhabdotheliosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, renal cell carcinoma, hematoma, bile duct carcinoma, melanoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell and non-small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocyoma, medulloblastoma, craniopharyngioma, ependynoma, pinealoma, retinoblastoma, rectal carcinoma, cancer of the thyroid, head and neck cancer, brain cancer, neuroblastoma, cancer of the endometrium, lymphoproliferative diseases, hematopoietic malignancies including all types of leukemia and lymphoma including: acute myelogenous leukemia, acute myelocytic leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, mast cell leukemia,

multiple myeloma, myeloid lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, as well as metastasis of all the above.

64. (New) A compound of Formula I:



Formula I

wherein:

n is 0, 1, or 2;

R_1 is OH, C_1 to C_{12} alkoxy, C_1 to C_{12} substituted alkoxy, aryloxy, O-glucosyl or imino;

R_2 is OH, C_1 to C_{12} alkoxy, C_1 to C_{12} substituted alkoxy, O-glucosyl, oxo, alkyl or imino;

R_3, R_4, R_5, R_6, R_7, A, B, C, D and E are each independently H, halogen, OH, C to C alkoxy, C to C substituted alkoxy, aryloxy, O-glucosyl, C_1 to C_{12} alkyl or C_1 to C_{12} substituted alkyl; provided that at least one of R_4, R_5, R_6, R_7, B, C, D or E is a halogen;

wherein R_1 and R_2, or R_1 and R_4 may form together a lactone which is optionally substituted;

wherein the bonds between C_3:C_7, C_4:C_5, and C_9:C_{10} may independently be double bonds or single bonds;

or a derivative of said formula, wherein the derivative has at least one of the following: a lower acyl side chain at C_3 (free acid or ester or conjugate), a keto or hydroxy (free hydroxy or ester) moiety at the C_6 carbon, or an n-pentenyl or n-pentyl side chain at C_7;

including salts, hydrates, solvates, polymorphs, optical isomers, enantiomers, diastereomers, and mixtures thereof.

65. (New) The compound of claim 64, wherein the bond between C_9 and C_{10} is a single bond.

66. (New) The compound of claim 64, wherein R_2 is oxo.

67. (New) The compound of claim 64, wherein R_1 is alkoxy.

68. (New) The compound of claim 64, wherein R_3, R_4 and R_5 are each H.

69. (New) The compound of claim 64, wherein C, D and E are each H.

70. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier, and as an active ingredient a compound of claim 64.

71. (New) A method for reduction of the growth of cancer cells, comprising exposing the cancer cells to a therapeutically effective amount of a compound of claim 64.

72. (New) A method for the treatment of cancer comprising administering to the subject in need thereof a pharmaceutical composition containing as an active ingredient a therapeutically effective amount of the compound according to claim 64.

73. (New) The method of claim 72, wherein the cancer is selected from the group consisting of carcinoma, sarcoma, adenoma, hepatocellular carcinoma, hepatoblastoma, rhabdomyosarcoma, esophageal carcinoma, thyroid carcinoma, ganglioblastoma, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphagiosarcoma, synovioama, Ewing's tumor, leimyosarcoma, rhabdotheliosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, renal cell carcinoma, hematoma, bile duct carcinoma, melanoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell and non-small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocyoma, medulloblastoma, craniopharyngioma, ependynoma, pinealoma, retinoblastoma, rectal carcinoma, cancer of the thyroid, head and neck cancer, brain cancer, neuroblastoma, cancer of the endometrium, lymphoproliferative diseases, hematopoietic malignancies including all types of leukemia and lymphoma including: acute myelogenous leukemia, acute myelocytic leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, mast cell leukemia, multiple myeloma, myeloid lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma.